ARDX
Ardelyx, Inc.
$6.78
-2.87%
2026-05-08
About Ardelyx, Inc.
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Key Fundamentals
Forward P/E
13.74
EPS (TTM)
$-0.24
ROE
-39.5%
Revenue Growth (YoY)
27.5%
Profit Margin
-13.6%
Debt/Equity
157.53
Price/Book
11.76
Beta
0.61
Market Cap
$1.75B
Avg Volume (10D)
5.3M
Recent Breakout Signals
No recent breakout signals detected for ARDX.
Recent Price Range (60 Days)
60D High
$7.43
60D Low
$5.11
Avg Volume
3.9M
Latest Close
$6.78
Get breakout alerts for ARDX
Sign up for Breakout Scanner to receive daily notifications when ARDX triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Ardelyx, Inc. (ARDX) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors ARDX daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. ARDX operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.